Physician profile
Christopher Allan Kellogg
NPI 1598260119
$2,007.69
in general payments reported to CMS, 2019-2025
22 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $109 · 2023: $545 · 2024: $786 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $422.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $373.22 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $163.02 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $110.30 | 2023-2025 | |
| Lilly USA, LLC | $101.16 | 2022-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $100.62 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $88.49 | 2023-2024 | Otezla, Repatha, Evenity |
| Pfizer INC. | $85.35 | 2023-2025 | |
| Abbvie INC. | $75.44 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $62.74 | 2022-2024 | Verquvo, Gardasil 9, Gardasil |
| Dexcom, INC. | $59.21 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $55.84 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $48.69 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Sumitomo Pharma America, INC. | $46.70 | 2024-2025 | Gemtesa |
| Baxter Healthcare | $44.71 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $34.93 | 2024-2025 | Rexulti |
| Insulet Corporation | $32.42 | 2024 | Omnipod |
| Shield Therapeutics INC | $27.69 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.46 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $22.99 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $15.08 | 2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.